{"organizations": [], "uuid": "ddfc21fdc52777808bc2338e1c90b87f8e9be4e8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-auris-medical-reports-new-data-hig/brief-auris-medical-reports-new-data-highlighting-superior-bioavailability-of-am-125-idUSFWN1PX1BM", "country": "US", "domain_rank": 408, "title": "BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T16:24:00.000+02:00", "replies_count": 0, "uuid": "ddfc21fdc52777808bc2338e1c90b87f8e9be4e8"}, "author": "", "url": "https://www.reuters.com/article/brief-auris-medical-reports-new-data-hig/brief-auris-medical-reports-new-data-highlighting-superior-bioavailability-of-am-125-idUSFWN1PX1BM", "ord_in_thread": 0, "title": "BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "auris medical holding ag", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 7, 2018 / 2:25 PM / in 7 minutes BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125 Reuters Staff \nFeb 7 (Reuters) - Auris Medical Holding AG: \n* AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE \n* AURIS MEDICAL HOLDING - SINGLE DOSE ANIMAL STUDY DEMONSTRATES 5 TO 35 TIMES HIGHER BIOAVAILABILITY OF INTRANASAL BETAHISTINE RELATIVE TO ORAL BETAHISTINE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-07T16:24:00.000+02:00", "crawled": "2018-02-07T16:34:01.010+02:00", "highlightTitle": ""}